Markets:

Overview

News

Currencies

International

Treasuries

BioNTech SE - American Depositary Shares (NQ:BNTX)

109.44 +0.51 (+0.47%)

Streaming Delayed Price Updated: 12:46 PM EST, Feb 11, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about BioNTech SE - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9

...

61 62 Next >

Moderna (MRNA) Deep Dive: Navigating Regulatory Blows and the Pivot to Oncology

Today 9:42 EST

Today, February 11, 2026, marks a volatile chapter for Moderna, Inc. (NASDAQ: MRNA). The biotechnology pioneer, which became a household name during the COVID-19 pandemic, finds itself at a critical...

Via Finterra

2 Biotech Stocks Set to Rebound in 2026 ↗

January 27, 2026

They could perhaps see sustained runs beyond this year.

Via The Motley Fool

Moderna and Merck Solidify Oncology Leadership as Five-Year Melanoma Data Fuels Market Rally

January 22, 2026

In a landmark moment for the future of personalized medicine, Moderna, Inc. (NASDAQ: MRNA) and Merck & Co., Inc. (NYSE: MRK) announced groundbreaking five-year follow-up data on January 20, 2026, for...

Via MarketMinute

Topics Intellectual Property

BNTX Shares Rise On Goldman Sachs Upgrade, Optimism For Cancer Portfolio ↗

January 16, 2026

Via Stocktwits

Earnings Scheduled For November 3, 2025 ↗

November 03, 2025

Via Benzinga

Moderna’s 2026 Pivot: From Pandemic Pioneer to Oncology Powerhouse

January 22, 2026

As of January 22, 2026, Moderna, Inc. (NASDAQ: MRNA) finds itself at a pivotal crossroads in its corporate evolution. Once the poster child for the global pandemic response, the Cambridge-based...

Via Finterra

Topics Artificial Intelligence Economy Intellectual Property

Moderna’s High-Stakes Transformation: Navigating the Post-Pandemic Pivot

January 14, 2026

Once the poster child for the biotechnology sector’s rapid response to the global pandemic, Moderna, Inc. (Nasdaq: MRNA) finds itself at a critical crossroads in early 2026. After a tumultuous period...

Via Finterra

Topics Initial Public Offering Intellectual Property

Trump’s Iran Tariff Threat Lit a Fuse Under Oil — and Wall Street Still Sold It ↗

January 14, 2026

Via Chartmill

Topics Government

The mRNA Pivot: Moderna Navigates Regulatory Headwinds and Tariff Turmoil in a Volatile 2026 Biotech Landscape

January 12, 2026

As the 44th Annual J.P. Morgan Healthcare Conference concludes in early January 2026, Moderna, Inc. (NASDAQ: MRNA) finds itself at a critical crossroads. Once the darling of the pandemic era, the...

Via MarketMinute

Topics Economy Intellectual Property World Trade

BioNTech Finalizes CureVac Acquisition: A Strategic Consolidation Met with Market Skepticism

January 09, 2026

In a move that signals the end of an era for independent mRNA pioneers, BioNTech SE (Nasdaq: BNTX) has officially completed its acquisition of longtime rival CureVac N.V. (Nasdaq: CVAC). The...

Via MarketMinute

Topics Intellectual Property

Moderna’s Second Act: A 2026 Deep Dive into the Future of mRNA Therapeutics

January 09, 2026

Today’s Date: January 9, 2026 Introduction As we enter the first weeks of 2026, Moderna, Inc. (NASDAQ: MRNA) finds itself at a defining crossroads. Once the poster child for the biotech boom of the...

Via PredictStreet

Topics Initial Public Offering Intellectual Property

Moderna’s Second Act: Analyzing the 2026 Pipeline Pivot and Recent Stock Surge

January 07, 2026

Date: January 7, 2026 Introduction Moderna, Inc. (NASDAQ: MRNA), once the definitive poster child of the COVID-19 pandemic response, is currently undergoing one of the most significant pivots in the...

Via PredictStreet

Topics Economy Initial Public Offering Intellectual Property

Genmab Stock Slips After Discontinuing Further Development Of Cancer Drug Developed With BioNTech ↗

December 29, 2025

The company has decided to concentrate on cancer therapies Epkinly, Petosemtamab and Rina‑S, which are in late-stage development.

Via Stocktwits

Topics Supply Chain

Moderna (MRNA) Deep-Dive: Navigating the 7.5% Year-End Slide and the Path to a 2028 Recovery

December 24, 2025

As of December 24, 2025, Moderna, Inc. (Nasdaq: MRNA) finds itself at a pivotal crossroads in its corporate evolution. Once the definitive success story of the pandemic era, the Cambridge-based...

Via PredictStreet

Topics Initial Public Offering

The Pfizer Pivot: A Deep-Dive into PFE’s 2025 Financial Recovery and Strategic Rebirth

December 22, 2025

As of today, December 22, 2025, Pfizer Inc. (NYSE: PFE) stands as a case study in corporate reinvention and the brutal reality of the post-pandemic "hangover." Once the darling of the global healthcare...

Via PredictStreet

Topics Economy Intellectual Property

Moderna (MRNA): The “Act 2” of an mRNA Pioneer – A 2025 Deep Dive

December 22, 2025

As of December 22, 2025, Moderna, Inc. (NASDAQ: MRNA) stands at a critical juncture in its corporate evolution. Once the poster child for the biotechnology industry’s rapid response to the global...

Via PredictStreet

Topics Earnings Initial Public Offering Intellectual Property

Pfizer's Muted 2026 Outlook Sends Ripples Through Pharmaceutical Sector

December 16, 2025

New York, NY – December 16, 2025 – Pfizer Inc. (NYSE: PFE) today delivered a sobering financial outlook for 2026, projecting revenue and adjusted earnings per share (EPS) that fell short of Wall...

Via MarketMinute

Topics Intellectual Property

Moderna, BioNTech Slammed After FDA Links Covid Shots To 10 Deaths ↗

December 01, 2025

Moderna tumbled Monday after an FDA director reportedly issued a memo that says Covid shots killed 10 children.

Via Investor's Business Daily

Topics Death

2 Top Dividend Stocks to Buy and Hold ↗

November 30, 2025

Patience will be rewarded for those who stick with these two healthcare stocks.

Via The Motley Fool

Topics Artificial Intelligence Intellectual Property

BioNTech (BNTX) Q3 2025 Earnings Call Transcript ↗

November 27, 2025

BioNTech (BNTX) Q3 2025 Earnings Call Transcript

Via The Motley Fool

Topics Earnings

Pfizer Seeks To Exit BioNTech Investment After Lucrative Covid Vaccine Run ↗

November 13, 2025

Pfizer plans to sell its remaining BioNTech stake through a $508 million block trade, ending a profitable Covid-19 vaccine partnership.

Via Benzinga

BioNTech Says Collaboration With Pfizer Going Strong After Report Indicated US Pharma Giant Considering Stake Sale In The German Company ↗

November 13, 2025

A BioNTech spokesperson told Reuters that the two companies continue to have a “close and strong collaboration.”

Via Stocktwits

BioNTech Sees Higher 2025 Sales Driven By Bristol Myers Partnership ↗

November 03, 2025

BioNTech reports a Q3 loss but boosts 2025 revenue forecast to €2.6–2.8 billion, driven by Bristol Myers collaboration and cost optimization.

Via Benzinga

BioNTech SE (NASDAQ:BNTX) Reports Mixed Q3 2025 Results with Major Revenue Beat and Quarterly Loss ↗

November 03, 2025

BioNTech Q3 2025: Revenue surges on a $1.5B partnership payment, but company posts a net loss. Full-year sales guidance was raised significantly.

Via Chartmill

Healthcare Sector Navigates Volatile Waters as S&P 500 Closes: A Deep Dive into Key Market Drivers

October 27, 2025

As the closing bell rings on October 27, 2025, the S&P 500 Healthcare sector stands at a critical juncture, exhibiting the nuanced volatility that defines this essential yet complex segment of the...

Via MarketMinute

Topics Artificial Intelligence Economy Intellectual Property

2 Unstoppable Dividend Stocks Yielding More Than 4% That Income-Seeking Investors Will Want to Buy in November and Hold Forever ↗

October 25, 2025

Both companies are monsters in their industry and are poised to thrive.

Via The Motley Fool

Topics Government Intellectual Property World Trade

Beyond The Numbers: 7 Analysts Discuss BioNTech Stock ↗

October 10, 2025

Via Benzinga

Ionis Pharmaceuticals (NASDAQ:IONS) Ascends to Six-Year High, Fueled by Breakthrough Pipeline and Robust Sales Outlook

October 08, 2025

Carlsbad, CA – October 8, 2025 – Ionis Pharmaceuticals (NASDAQ:IONS) is currently witnessing a remarkable surge in its stock value, nearing a six-year high. This impressive ascent is largely driven by...

Via MarketMinute

Healthcare Stocks Are Rising: Here Are 2 With Even More Upside Ahead ↗

October 08, 2025

These biotechs could finally come into their own by the end of the decade.

Via The Motley Fool

Topics Government World Trade

Healthcare Sector Shines Amidst Market Turbulence, Bolstering S&P 500 Resilience

October 02, 2025

On October 2, 2025, the Healthcare sector emerged as a beacon of stability and growth within the S&P 500, delivering a robust positive performance that significantly contributed to the broader market's...

Via MarketMinute

Topics Artificial Intelligence Economy Stocks

< Previous 1 2 3 4 5 6 7 8 9

...

61 62 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.